P692: THE KEAP1-NRF2 REDOX PATHWAY IS OF CENTRAL IMPORTANCE DURING 5-AZACYTIDINE THERAPY AND THE DEVELOPMENT OF RESISTANCE VIA A SPECIFIC SET OF PROTEIN OXIDATIVE MODIFICATIONS

por Pimková, Kristýna, Minařík, Lubomír, Myšáková, Michaela, Kokavec, Juraj, Stopka, Tomáš
Publicado 2023

Combined Approach to Leukemic Differentiation Using Transcription Factor PU.1-Enhancing Agents

por Bašová, Petra, Paszeková, Helena, Minařík, Lubomír, Dluhošová, Martina, Burda, Pavel, Stopka, Tomáš
Publicado 2022

Somatic mutation dynamics in MDS patients treated with azacitidine indicate clonal selection in patients-responders

por Polgarova, Kamila, Vargova, Karina, Kulvait, Vojtech, Dusilkova, Nina, Minarik, Lubomir, Zemanova, Zuzana, Pesta, Michal, Jonasova, Anna, Stopka, Tomas
Publicado 2017

G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial

por Stopka, Tomáš, Minařík, Lubomír, Dusilková, Nina, Pešta, Michal, Kulvait, Vojtěch, Špaček, Martin, Zemanová, Zuzana, Kalousová, Marta, Jonášová, Anna
Publicado 2022

Analysis of 5-Azacytidine Resistance Models Reveals a Set of Targetable Pathways

por Minařík, Lubomír, Pimková, Kristýna, Kokavec, Juraj, Schaffartziková, Adéla, Vellieux, Fréderic, Kulvait, Vojtěch, Daumová, Lenka, Dusilková, Nina, Jonášová, Anna, Vargová, Karina Savvulidi, Králová Viziová, Petra, Sedláček, Radislav, Zemanová, Zuzana, Stopka, Tomáš
Publicado 2022